Anti-NMDA receptor encephalitis as a reversible cause of acute psychoses: Diagnostic possibilities. (Comment on the article by E.V. Snedkov "Is anti-NMDA receptor encephalitis real? I. Diagnostic challenges")

Abstract

Encephalitis with antibodies to NMDA receptors is a form of autoimmune encephalitis that most often debuts as an acute psychosis. Considering its curability and reversibility, encephalitis with antibodies to NMDA receptors must be included into differential diagnostic list for all the patients suffering first psychotic episode. However, to diagnose it, it is necessary to follow a step-by-step algorithm considering both clinical and instrumental and laboratory data. Confirming anti-NMDA-receptor encephalitis based solely on increased blood antibodies level often leads to false-positive diagnostics and errors in treatment of such patients. In this article, we discuss diagnostic features of encephalitis with antibodies to NMDA receptors, as well as other forms of autoimmune encephalitis that can initially manifest as acute psychoses.

Keywords

encephalitis with antibodies to NMDA receptors / psychosis / autoimmune encephalitis / teratoma

References

[1] Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–1098.

[2] Dalmau J., Gleichman A.J., Hughes E.G. et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies // Lancet Neurol. 2008. Vol. 7. P. 1091–1098.

[3] Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.

[4] Dalmau J., Tuzun E., Wu H.Y. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma // Ann. Neurol. 2007. Vol. 61. Р. 25–36.

[5] Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840–851.

[6] Dalmau J., Graus F. Antibody-mediated encephalitis // N. Engl. J. Med. 2018. Vol. 378. P. 840–851.

[7] Dalmau J, Armangué T, Planagumà J et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057. DOI: 10.1016/S1474-4422(19)30244-3. PMID: 31326280.

[8] Dalmau J., Armangué T., Planagumà J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models // Lancet Neurol. 2019. Vol. 18. N. 11. P. 1045–1057. DOI: 10.1016/S1474-4422(19)30244-3. PMID: 31326280.

[9] Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev. 2011;7:189–193.

[10] Kayser M.S., Dalmau J. Anti-NMDA receptor encephalitis in psychiatry // Curr. Psychiatry Rev. 2011. Vol. 7. P. 189–193.

[11] Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol. 2013;70:1133–1139.

[12] Kayser M.S., Titulaer M.J., Gresa-Arribas N., Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis // JAMA Neurol. 2013. Vol. 70. P. 1133–1139.

[13] Mannara F, Radosevic M, Planagumà J et al. Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. Brain. 2020;143(9):2709–2720. DOI: 10.1093/brain/awaa195. PMID: 32830245.

[14] Mannara F., Radosevic M., Planagumà J. et al. Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis // Brain. 2020. Vol. 143. N. 9. P. 2709–2720. DOI: 10.1093/brain/awaa195. PMID: 32830245.

[15] Aperia A, Greengard P. Dopamine receptor response to NMDA stimulation. Am J Psychiatry. 2006;163(10):1682. DOI: 10.1176/ajp.2006.163.10.1682. PMID: 17012674.

[16] Aperia A., Greengard P. Dopamine receptor response to NMDA stimulation // Am. J. Psychiatry. 2006. Vol. 163. N. 10. P. 1682. DOI: 10.1176/ajp.2006.163.10.1682. PMID: 17012674.

[17] David AS. The psychiatric phenotype of anti-NMDA receptor encephalitis. J Neuropsychiatry Clin Neurosci. 2019;31:70–79.

[18] David A.S. The psychiatric phenotype of anti-NMDA receptor encephalitis // J. Neuropsychiatry Clin. Neurosci. 2019. Vol. 31. P. 70–79.

[19] Sarkis RA, Coffey MJ, Cooper JJ et al. Anti-N-methyl-D-aspartate receptor encephalitis: A review of psychiatric phenotypes and management considerations: A report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2019;31:137–142.

[20] Sarkis R.A., Coffey M.J., Cooper J.J. et al. Anti-N-methyl-D-aspartate receptor encephalitis: A review of psychiatric phenotypes and management considerations: A report of the American Neuropsychiatric Association Committee on Research // J. Neuropsychiatry Clin. Neurosci. 2019. Vol. 31. P. 137–142.

[21] Al-Diwani A, Handel A, Townsend L et al. The psychopathology of NMDAR-antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6:235–246.

[22] Al-Diwani A., Handel A., Townsend L. et al. The psychopathology of NMDAR-antibody encephalitis in adults: A systema-tic review and phenotypic analysis of individual patient data // Lancet Psychiatry. 2019. Vol. 6 . P. 235–246.

[23] Cullen AE, Palmer-Cooper EC, Hardwick M et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: A meta-analysis of cross-sectional and case-control studies. Lancet Psychiatry. 2021;8(2):109–120. DOI: 10.1016/S2215-0366(20)30432-6. PMID: 33357497.

[24] Cullen A.E., Palmer-Cooper E.C., Hardwick M. et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: A meta-analysis of cross-sectional and case-control studies // Lancet Psychiatry. 2021. Vol. 8. N. 2. P. 109–120. DOI: 10.1016/S2215-0366(20)30432-6. PMID: 33357497.

[25] González-García S, González-Quevedo A, Hernandez-Diaz Z et al. Circulating autoantibodies against the NR2 peptide of the NMDA receptor are associated with subclinical brain damage in hypertensive patients with other pre-existing conditions for vascular risk. J Neurol Sci. 2017;375:324–330. DOI: 10.1016/j.jns.2017.02.028. PMID: 28320161.

[26] González-García S., González-Quevedo A., Hernandez-Diaz Z. et al. Circulating autoantibodies against the NR2 peptide of the NMDA receptor are associated with subclinical brain damage in hypertensive patients with other pre-existing conditions for vascular risk // J. Neurol. Sci. 2017. Vol. 375. P. 324–330. DOI: 10.1016/j.jns.2017.02.028. PMID: 28320161.

[27] Ehrenreich H. Autoantibodies against N-methyl-D-aspartate receptor 1 in health and disease. Curr Opin Neurol. 2018;31(3):306–312. DOI: 10.1097/WCO.0000000000000546. PMID: 29474316. PMCID: PMC5959203.

[28] Ehrenreich H. Autoantibodies against N-methyl-D-aspartate receptor 1 in health and disease // Curr. Opin. Neurol. 2018. Vol. 31. N. 3. P. 306–312. DOI: 10.1097/WCO.0000000000000546. PMID: 29474316. PMCID: PMC5959203.

[29] Venkatesan A, Tunkel AR, Bloch KC et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57(8):1114–1128. DOI: 10.1093/cid/cit458. PMID: 23861361. PMCID: PMC3783060.

[30] Venkatesan A., Tunkel A.R., Bloch K.C. et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium // Clin. Infect. Dis. 2013. Vol. 57. N. 8. P. 1114–1128. DOI: 10.1093/cid/cit458. PMID: 23861361. PMCID: PMC3783060.

[31] Blackman G, Lim MF, Pollak T et al. The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: A systematic review and meta-analysis of individual patient data. J Neurol. 2022;269(10):5302–5311. DOI: 10.1007/s00415-022-11224-6. PMID: 35790561. PMCID: PMC9467941.

[32] Blackman G., Lim M.F., Pollak T. et al. The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: A systematic review and meta-analysis of individual patient data // J. Neurol. 2022. Vol. 269. N. 10. P. 5302–5311. DOI: 10.1007/s00415-022-11224-6. PMID: 35790561. PMCID: PMC9467941.

[33] Dahm L, Ott C, Steiner J et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Annals of Neurology. 2014;76(1):82–94. DOI: 10.1002/ana.24189.

[34] Dahm L., Ott C., Steiner J. et al. Seroprevalence of autoantibodies against brain antigens in health and disease // Annals of Neurology. 2014. Vol. 76. N. 1. P. 82–94. DOI: 10.1002/ana.24189.

[35] Seery N, Butzkueven H, O’Brien TJ, Monif M. Contemporary advances in anti-NMDAR antibody (Ab)-mediated encepha-litis. Autoimmun Rev. 2022;21(4):103057. DOI: 10.1016/j.autrev.2022.103057. PMID: 35092831.

[36] Seery N., Butzkueven H., O’Brien T.J., Monif M. Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis // Autoimmun. Rev. 2022. Vol. 21. N. 4. P. 103057. DOI: 10.1016/j.autrev.2022.103057. PMID: 35092831.

[37] Platt MP, Agalliu D, Cutforth T. Hello from the other side: How autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol. 2017;8:442. DOI: 10.3389/fimmu.2017.00442. PMID: 28484451. PMCID: PMC5399040.

[38] Platt M.P., Agalliu D., Cutforth T. Hello from the other side: How autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis // Front. Immunol. 2017. Vol. 8. P. 442. DOI: 10.3389/fimmu.2017.00442. PMID: 28484451. PMCID: PMC5399040.

[39] Swayne A, Warren N, Prain K et al. Analysing triggers for anti-NMDA-receptor encephalitis including herpes simplex virus encephalitis and ovarian teratoma: Results from the Queensland Autoimmune Encephalitis cohort. Intern Med J. 2022;52(11):1943–1949. DOI: 10.1111/imj.15472. PMID: 34339078.

[40] Swayne A., Warren N., Prain K. et al. Analysing triggers for anti-NMDA-receptor encephalitis including herpes simplex virus encephalitis and ovarian teratoma: Results from the Queensland Autoimmune Encephalitis cohort // Intern. Med. J. 2022. Vol. 52. N. 11. P. 1943–1949. DOI: 10.1111/imj.15472. PMID: 34339078.

[41] Jang Y, Lee K, Lee C et al. Teratoma pathology and genomics in anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2023. DOI: 10.1002/acn3.51948. Epub ahead of print. PMID: 37986706.

[42] Jang Y., Lee K., Lee C. et al. Teratoma pathology and genomics in anti-NMDA receptor encephalitis // Ann. Clin. Transl. Neurol. 2023. DOI: 10.1002/acn3.51948. Epub ahead of print. PMID: 37986706.

[43] Al-Diwani A, Theorell J, Damato V et al. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. Brain. 2022;145(8):2742–2754. DOI: 10.1093/brain/awac088. PMID: 35680425. PMCID: PMC9486890.

[44] Al-Diwani A., Theorell J., Damato V. et al. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis // Brain. 2022. Vol. 145. N. 8. P. 2742–2754. DOI: 10.1093/brain/awac088. PMID: 35680425. PMCID: PMC9486890.

[45] Makuch M, Wilson R, Al-Diwani A et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications. Ann Neurol. 2018;83(3):553–561. DOI: 10.1002/ana.25173. PMID: 29406578. PMCID: PMC5925521.

[46] Makuch M., Wilson R., Al-Diwani A. et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications // Ann. Neurol. 2018. Vol. 83. N. 3. P. 553–561. DOI: 10.1002/ana.25173. PMID: 29406578. PMCID: PMC5925521.

[47] Sancho-Saúco J, Corraliza-Galán V, Lázaro-Carrasco de la Fuente J et al. Anti-NMDA receptor encephalitis: Two case reports associated with ovarian teratoma and a literature review. J Obstet Gynaecol. 2019;39(6):864–865. DOI: 10.1080/01443615.2019.1579175. PMID: 31017481.

[48] Sancho-Saúco J., Corraliza-Galán V., Lázaro-Carrasco de la Fuente J. et al. Anti-NMDA receptor encephalitis: Two case reports associated with ovarian teratoma and a literature review // J. Obstet. Gynaecol. 2019. Vol. 39. N. 6. P. 864–865. DOI: 10.1080/01443615.2019.1579175. PMID: 31017481.

[49] Armangue T, Spatola M, Vlagea A et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–772. DOI: 10.1016/S1474-4422(18)30244-8. PMID: 30049614. PMCID: PMC6128696.

[50] Armangue T., Spatola M., Vlagea A. et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis // Lancet Neurol. 2018. Vol. 17. N. 9. P. 760–772. DOI: 10.1016/S1474-4422(18)30244-8. PMID: 30049614. PMCID: PMC6128696.

[51] Nosadini M, Mohammad SS, Corazza F et al. Herpes simplex virus-induced anti-N-methyl-D-aspartate receptor encephalitis: A systematic literature review with analysis of 43 cases. Dev Med Child Neurol. 2017;59(8):796–805. DOI: 10.1111/dmcn.13448. PMID: 28439890.

[52] Nosadini M., Mohammad S.S., Corazza F. et al. Herpes simplex virus-induced anti-N-methyl-D-aspartate receptor encephalitis: A systematic literature review with analysis of 43 cases // Dev. Med. Child Neurol. 2017. Vol. 59. N. 8. P. 796–805. DOI: 10.1111/dmcn.13448. PMID: 28439890.

[53] Prüss H. Postviral autoimmune encephalitis: manifestations in children and adults. Curr Opin Neurol. 2017;30(3):327–333. DOI: 10.1097/WCO.0000000000000445. PMID: 28234798.

[54] Prüss H. Postviral autoimmune encephalitis: Manifestations in children and adults // Curr. Opin. Neurol. 2017. Vol. 30. N. 3. P. 327–333. DOI: 10.1097/WCO.0000000000000445. PMID: 28234798.

[55] Vasenina EE, Levin OS, Gan’kina OA et al. Autoimmune anti-NMDA-R encephalitis. Zh Nevrol Psikhiatr im SS Korsakova. 2017;117(2):110–116. (In Russ.) DOI: 10.17116/jnevro201711721110-116. PMID: 28374703.

[56] Васенина Е.Е., Левин О.С., Ганькина О.А. и др. Аутоиммунный энцефалит с антителами к Nmda рецепторам. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017. №2: 110–116. DOI: 10.17116/jnevro201711721110-116. EDN: YHEQKX.

[57] Podzolkova NM, Korennaya VV, Levin OS et al. Autoimmunny`ĭ e`ncefalit s antitelami k receptoram N-metil-D-aspartata i teratomy` yaichnikov: sushhestvuet li vzaimosvyaz`? Voprosy` ginekologii, akusherstva i perinatologii. 2020;19(5):124–131. (In Russ.) DOI: 10.20953/1726-1678- 2020-5-124-131.

[58] Подзолкова Н.М., Коренная В.В., Левин О.С. и др. Аутоиммунный энцефалит с антителами к рецепторам N-метил-D-аспартата и тератомы яичников: существует ли взаимосвязь? // Вопросы гинекологии, акушерства и перинатологии. 2020. Т. 19. №5. С. 124–131. DOI: 10.20953/1726-1678- 2020-5-124-131.

[59] Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77:589–593.

[60] Martinez-Hernandez E., Horvath J., Shiloh-Malawsky Y. et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis // Neurology. 2011. Vol. 77. P. 589–593.

[61] Bien CG, Vincent A, Barnett MH et al. Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis. Brain. 2012;135:1622–1638.

[62] Bien C.G., Vincent A., Barnett M.H. et al. Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis // Brain. 2012. Vol. 135. P. 1622–1638.

[63] Nissen MS, Ryding M, Meyer M, Blaabjerg M. Autoimmune encephalitis: Current knowledge on subtypes, disease mechanisms and treatment. CNS Neurol Disord Drug Targets. 2020;19(8):584–598. DOI: 10.2174/1871527319666200708133103. PMID: 32640967.

[64] Nissen M.S., Ryding M., Meyer M., Blaabjerg M. Autoimmune encephalitis: Current knowledge on subtypes, disease mechanisms and treatment // CNS Neurol. Disord. Drug Targets. 2020. Vol. 19. N. 8. P. 584–598. DOI: 10.2174/1871527319666200708133103. PMID: 32640967.

[65] Parwani J, Ortiz JF, Alli A et al. Understanding seizures and prognosis of the extreme delta brush pattern in anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: A systematic review. Cureus. 2021;13(9):e18154. DOI: 10.7759/cureus.18154. PMID: 34589370. PMCID: PMC8460549.

[66] Parwani J., Ortiz J.F., Alli A. et al. Understanding seizures and prognosis of the extreme delta brush pattern in anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: A systematic review // Cureus. 2021. Vol. 13. N. 9. P. e18154. DOI: 10.7759/cureus.18154. PMID: 34589370. PMCID: PMC8460549.

[67] Castellano J, Glover R, Robinson J. Extreme delta brush in NMDA receptor encephalitis. Neurohospitalist. 2017;7(3):NP3–NP4. DOI: 10.1177/1941874416673191. PMID: 28634511. PMCID: PMC5467816.

[68] Castellano J., Glover R., Robinson J. Extreme delta brush in NMDA receptor encephalitis // Neurohospitalist. 2017. Vol. 7. N. 3. P. NP3–NP4. DOI: 10.1177/1941874416673191. PMID: 28634511. PMCID: PMC5467816.

[69] Gillinder L, Warren N, Hartel G et al. EEG findings in NMDA encephalitis — A systematic review. Seizure. 2019;65:20–24. DOI: 10.1016/j.seizure.2018.12.015. PMID: 30597400.

[70] Gillinder L., Warren N., Hartel G. et al. EEG findings in NMDA encephalitis — A systematic review // Seizure. 2019. Vol. 65. P. 20–24. DOI: 10.1016/j.seizure.2018.12.015. PMID: 30597400.

[71] Freund B, Ritzl EK. A review of EEG in anti-NMDA receptor encephalitis. J Neuroimmunol. 2019;332:64–68. DOI: 10.1016/j.jneuroim.2019.03.010. PMID: 30959339.

[72] Freund B., Ritzl E.K. A review of EEG in anti-NMDA receptor encephalitis // J. Neuroimmunol. 2019. Vol. 332. P. 64–68. DOI: 10.1016/j.jneuroim.2019.03.010. PMID: 30959339.

[73] Pollak TA, Lennox BR, Müller S et al. Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020;7(1):93–108. DOI: 10.1016/S2215-0366(19)30290-1. PMID: 31669058.

[74] Pollak T.A., Lennox B.R., Müller S. et al. Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin // Lancet Psychiatry. 2020. Vol. 7. N. 1. P. 93–108. DOI: 10.1016/S2215-0366(19)30290-1. PMID: 31669058.

RIGHTS & PERMISSIONS

Eco-Vector